Format

Send to

Choose Destination
J Cell Biochem. 2006 Feb 1;97(2):226-32.

Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.

Author information

1
Department of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York 14642, USA. Allen.Anandarajah@urmc.rochester.edu

Abstract

Focal bone loss around inflamed joints in patients with autoimmune disease, such as rheumatoid arthritis, remains a serious clinical problem. The recent elucidation of the RANK/RANK-ligand/OPG pathway and its role as the final effector of osteoclastogenesis and bone resorption has brought a tremendous understanding of the pathophysiology of inflammatory bone loss, and has heightened expectation of a novel intervention. Here, we review the etiology of inflammatory bone loss, the RANK/RANK-ligand/OPG pathway, and the clinical development of anti-RANK-ligand therapy.

PMID:
16240334
DOI:
10.1002/jcb.20674
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center